On October 16th, 2019, the Antimicrobial Drugs Advisory Committee (AMDAC) reviewed.
On October 16th, 2019, the Antimicrobial Drugs Advisory Committee (AMDAC) reviewed the New Drug Application (NDA) 209445 for cefiderocol lyophilized powder (Shionogi Inc.) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis due to gram-negative bacteria in patients with limited or no alternative treatment options.
FETROJA is a cephalosporin antibacterial drug product consisting of cefiderocol sulfate tosylate for intravenous infusion. Like the other cephalosporins, it penetrates the outer cell membrane of gram-negative pathogens and binds to penicillin-binding proteins to inhibit cell wall synthesis. Cefiderocol’s unique siderophore structure both enhances its membrane permeability and increases stability against lactamases.
As evidence, Shionogi Inc. presented the results from a pivotal phase-III study and an open-label study. APEKS-cUTI study, a multinational, multicenter, double-blind clinical trial,evaluated the efficacy and safety of FETROJA versus imipenem/cilastatin (IPM/CS) in patients with cUTI. The open-label CREDIBLE-CR study evaluated the new drug against best available therapy in 150 patients with serious gram-negative infections involving nosocomial pneumonia, sepsis, or drug-resistant cUTI.
This meeting consisted of 1 discussion question and 1 voting question. The voting question asked whether the Sponsor provided substantial evidence of efficacy and safety of cefiderocol for the proposed indication. The vote resulted in 14 YES, 2 NO, and 0 ABSTENTION.
The committee members in support of approval felt that the cUTI study was well designed and demonstrated meaningful effects. Those who opposed approval expressed concern that the open-label study found that cefiderocol was associated with an increased risk of mortality. Despite the approval, panelist consistently remarked on the need for further studies.
The agency is not obligated to follow its panel’s recommendation, yet normally does so, and did in this case.
On November 14th, 2019, the FDA gave cefiderocol an approval based on limited clinical safety and efficacy data for the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible gram-negative microorganisms, who have limited or no alternative treatment options. The FDA informed Shionogi that they are required to conduct further postmarketing safety surveillance including pediatric safety studies in accordance with the Pediatric Research Equity Act. The approval letter outlined the design and reporting requirements for each study.
ISS has two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us